Atezolizumab plus Bevacizumab in Cancer

All 222 patients intravenously received atezolizumab 1200 mg plus bevacizumab 15 mg/kg once every 3 weeks. If any unacceptable or serious AE related to the drug occurred, the administration was interrupted until symptoms diminished to grade 1 or 2. The patients continued treatment until the treatment failed or an unacceptable AE occurred. The relative intensity of bevacizumab was defined as the ratio of the amount of the actual dose to the standard dose until the treatment was discontinued. Data on AEs were collected during treatment, and AEs were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.